Brain Tumor Related News!
Fundraisers For Brain Tumor Research!
Brain Tumor Conferences / Events
New Clinical Trials
Noteworthy Treatments Explanation of the new high tech treatments!
Conferences / Events
- No events scheduled. Please check back soon!
Brain Tumor News!
Note: The comments under each article title are the opinion of our president, Al Musella, DPM, and do not reflect official policy of the Musella Foundation!
Displaying Stories 1 to 20 of 6,601
11/13/19 Clinical Efficacy of Weekly ONC201 in Adult Recurrent Glioblastoma Published
This study population was all recurrent GBM patients - not limited to the H3K27M mutant tumors as the current trials are.. They did have one patient, who has the H3K27M mutation, who had multifocal recurrent gbm and had a complete response that has lasted a year and a half so far. They are now testing this drug in clinical trials only with tumors that have this mutation. So althought the study did not hit the target endpoint of progression free survival at 6 months, there were a few positives from the study: They think they found the biomarker (H3K27M) that identifies patients where it has a better chance of helping, and they found that the drug gets to the tumor at the correct concentration - it gets through the blood brain barrier. It is also safe.
10/24/19 GBM patient and Caregiver Survey
This is from our friends at PinPoint Patient Recruiting. They will pay you to take a survey, and will make a donation to the Musella Foundation. Let me know if you do the survey!
10/22/19 Donate or request expensive medicines!
We frequently get asked if we can accept unopened Temodar and until now had to say no!
Our copay assistance program helps only if you have insurance. For those without insurance, we can't help but this place may be able to help!
10/10/19 First-line treatment of ONC 201 in newly diagnosed DIPG pediatric patients is now open.
There are a few trials of this drug, as well as the compassionate use program, but a new trial opened that requires DIPG patients to start before radiation. It is hard to get the word out to those patients since things happen so fast when first diagnosed and most families are in shock. So if you hear of a patient diagnosed with DIPG, mention this trial to them as an option.
Disclaimer: The Musella Foundation gave a venture philanthropy grant to the company that makes Onc-201 - which means the foundation gets a return if the drug is successful.
10/10/19 Oncology Pioneer xCures Names Experts to Advisory Boards
We are partnering with this company (and Cancer Commons) to track the patients in our Onc-201 compassionate use program. We are testing a program that will allow our patients to utilize xCures' services at no cost to the patients or to the Musella Foundation. xCures will evaluate a patient’s case, figure out the best treatment options using a combination of artificial intelligence, nurse navigators, research scientists, internal tumor board and an external virtual tumor board. xCures will then present the options to the patient who then decides with their own medical team which option to pursue. xCures will then help them get access to the treatments if needed, and then follow up to see how it works out, both to add knowledge to their knowledge base and to help again if there is a recurrence.
Disclaimer: I am a paid consultant for this company and I am an investor.
10/09/19 Any Amazon users?
Please help us raise money to allow this project (mentioned below) to continue. It is the most important project we ever funded and is making a huge difference in kids and young adult lives right now, and will hopefully speed up approval of the drug so that all those who need it can get it.
Disclaimer: This grant is venture philanthropy - which means if it is successful, the Musella Foundation will get a return.
09/30/19 Optune Open House
From our good friends at Novocure! These Open Houses are valuable to anyone who has a brain tumor or knows someone with a brain tumor!
09/13/19 Tocagen Reports Results of Toca 5 Phase 3 Trial in Recurrent Brain Cancer
Unfortunately the trial did not meet it's endpoint of median overall survival. I did not really expect it to as the immunotherapies appear to help only a small subset of patients, but when they do - it helps a lot. This leads to a long tail of survivors, but the median does not change. All of the immunotherapies by themselves will probably have this same problem. I think the key is to combine them to the point where most people benefit. I wouldn't write this off until we see the complete results and see if there is a signficant tail.
09/11/19 Frankly Speaking About Brain Tumors
This is from our good friends at the National Brain Tumor Society, the Cancer Support Community and Gilda's Club. It is an introduction to brain tumors. Everyone should read it.
09/09/19 Bristol-Myers Squibb's Opdivo fails 3rd straight test in tough-to-treat brain cancer
As I understand it, the failure was that the median progression free survival did not improve by adding Opdivo to the standard chemoradiation. This is not surprising as most of the immunotherapies seem to work really well on a small subset of the population. We see this in a long tail of survivors. However, even when there is an impressive improvement in long term survival in less than 50% of the patients, the median survival would not be expected to change much. This data has to be looked at closely to try to identify patients who were helped, and then try it in that subset of patient, perhaps in combination with other immunotherapies.
Displaying Stories 1 to 20 of 6601